MedPath

Study of the safety concernig autolougaus adipose tissue-derived stem cells for osteoarthritis of knee joint.

Phase 1
Conditions
Knee osteoarthritis
Registration Number
JPRN-jRCTb040190123
Lead Sponsor
Tsutsumi Mikihiro
Brief Summary

In this study, knee osteoarhritis was treated with autologous Lipogems products. There were 5 females aged 56 to 63 years old (mean 60 years old), who were 2 as grade II, 2 as grade II and one as grade IV of (K-L). Clinical evaluation was performed at 1 week, 1, 3 and 6 months after the operation, and no adverse event was observed. Both VAS and KOOS were significantiy increased after surgery, suggesting that treatment with Lipogems products for patients with knee osteoarthraitis may be safe and useful.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
5
Inclusion Criteria

1) 30 to 85 years of age
2) grade II-IV (Kellgren-Lawrence) by X-ray
3) persistent symptoms for more than 6 months
4) failure of conservative management
5) possibility general anesthesia

Exclusion Criteria

1)History of active neoplasm and active inflammatory disease
2) severe symptom by cerebral infarction and pulmonary infarction
3) rheumatoid arthritis and gout
4) pregnancy or lactation
5) thrombocytopenia
6) participation in other clinical studies
7) positive test result against HIV, HBV, HCV, syphilis or HTLV-1
8) severe DM, heart failure or renal failure.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Adverse events
Secondary Outcome Measures
NameTimeMethod
improvement effect
© Copyright 2025. All Rights Reserved by MedPath